|  |
| --- |
| November 15, 2013 |
|  |
|  |
| Contact person specialized pressDr. Jürgen KrauterCommunication, Health & NutritionPhone +49 6181 59-6847 Fax +49 6181 59-76847Juergen.krauter@evonik.com |
| Evonik Industries AGRellinghauser Straße 1-1145128 EssenGermanyPhone +49 201 177-01Telefax +49 201 177-3475www.evonik.de**Supervisory Board**Dr. Werner Müller, ChairmanExecutive BoardDr. Klaus Engel, ChairmanDr. Thomas Haeberle, Thomas Wessel, Patrik Wohlhauser, Ute Wolf, Dr. Dahai YuRegistered office EssenRegistered courtEssen local courtCommercial registry B 19474VAT ID no. DE 811160003 |

**Evonik positions itself in oncology**

Essen. Evonik Industries has launched a new website aimed specifically at manufacturers of oncology drugs. The new site, www.evonik.com/oncology-drugs, provides pharmaceutical companies with an overview of Evonik's competencies in this space. They include a proven track record in production of high-potency actives, development of drug delivery systems, generation of clinical samples, and commercial-scale manufacture of parenteral oncology drug products.

“The development and manufacturing of effective cancer drugs present significant challenges. Evonik with its broad competencies can help pharmaceutical companies overcome these hurdles and accelerate the development process." said Dr. Jean-Luc Herbeaux, the head of the Health Care Business Line of Evonik.

The new website describes the company’s Hanau, Germany, and Tippecanoe, U.S., sites’ capacities to produce highly potent active pharmaceutical ingredients (HPAPIs) in any volume from laboratory to commercial scale.

It also describes the pharmaceutical polymer platforms of Evonik, EUDRAGIT® and RESOMER®, which afford options to manufacture intelligent drug delivery systems for oral and parenteral administration. Thanks to their targeted and controlled release, these polymers contribute to reducing the dosage and cancer therapy length for the patient's benefit.

Evonik is also able to support pharmaceutical companies with formulation development. To give an example, Evonik has expertise in spray drying and melt extrusion, which can overcome the bioavailability problems that frequently occur with HPAPIs.

The company's certified facilities in Darmstadt, Germany and Birmingham, U.S. allow for the production of clinical samples for phase II (oral) and III (parenteral) trials. The Birmingham site is also equipped to produce a broad spectrum of complex parenteral drug systems for cancer therapies, such as micro-size and nanoparticles, liposomes, or lyophilisates.

"Thanks to our global presence, competencies in many areas of drug development, unique technologies and ultra-high quality standards, we are well positioned to support our pharmaceutical customers in their development projects," notes Herbeaux.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.